Cannabis Patents
A patent for an invention is the grant of a property right to the inventor, issued by the United States Patent and Trademark Office. Generally, the term of a new patent is 20 years from the date on which the application for the patent was filed in the United States or, in special cases, from the date an earlier related application was filed, subject to the payment of maintenance fees. U.S. patent grants are effective only within the United States, U.S. territories, and U.S. possessions. Under certain circumstances, patent term extensions or adjustments may be available.
The right conferred by the patent grant is, in the language of the statute and of the grant itself, “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States or “importing” the invention into the United States. What is granted is not the right to make, use, offer for sale, sell or import, but the right to exclude others from making, using, offering for sale, selling or importing the invention. Once a patent is issued, the patentee must enforce the patent without aid of the USPTO.
There are three types of patents: Utility, Design and Plant. — United States Patent and Trademark Office
Below is a Library of Cannabis Patents.
Synergistic Use of Cannabis for Treating Multiple Myeloma
One World Cannabis LTD | October 2018Abstract: “The present invention discloses a pharmaceutical composi tion comprising therapeutically effective amount of , or an extract consisting essentially therapeutically effective amount of at least one cannabinoid selected from the group consisting of : Cannabidiol ( CBD ) or a derivative thereof , Tetrahydrocannabinol ( THC ) or a derivative thereof, and any combination thereof , for use in the treatment of multiple myeloma ( MM ). The present invention further discloses methods and uses of the aforementioned composition ” — Patent US 2018/0303791 A1
Cannabidiol for Treatment of Severe and Refractory Graft-Versus-Host Disease
Moshe Yeshurun | February 2018Abstract: “ A method for treating a subject afflicted with acute graft versus host disease (GVHD) or chronic GVHD comprising administering to said subject a therapeutically effective amount of a composition comprising a cannabidiol (CBD), (−)-7-hydroxy-CBD, (−)-CBD-7-oic acid, dimethylheptyl homologue of (−)-7-hydroxy-CBD, or dimethylheptyl homologue of (−)-CBD-7-oic acid, thereby treating a subject afflicted with acute graft versus host disease (GVHD) or chronic GVHD wherein the composition is administered daily in doses of between 5 mg to 600 mg.” — Patent US9889100B2
Composition of Cannabinoids, Odorous Volatile Compounds, and Emu Oil for Topical Application, and a Method for Cannabinoid Transdermal Delivery
Gary and Vickie Lowe | Cannariginals & Theramu | December 2016Abstract: “A composition of cannabinoids, odorous volatile compounds, and emu oil for topical application, and a method for cannabinoid transdermal delivery wherein said composition effects increased delivery of cannabidinol to targeted areas in the hypodermis for therapeutic treatment therein whereby inflammation and other symptomology is alleviated and convalescence assisted.” — Patent US9526752 B1
Tetrahydrocannabivarin (THCV) For Use in the Treatment of Nausea and Vomiting
GW Pharma Limited | March 2016Abstract: “The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.” — United States Patent 20160074357
Sublingual Cannabis Dosage Form and Methods of Making and Using the Same
Ardent Llc, Shanel A. Lindsay, Laurence O. Mckinney | May 2015Abstract: “The present invention relates to a sublingual dosage form comprising decarboxylated cannabis plant material, and a dispenser for delivering at least one pharmacologically active cannabinoid from the decarboxylated cannabis plant material contained inside the dispenser into the sublingual cavity of a subject when the dispenser is placed within the subject’s sublingual cavity with the decarboxylated cannabis plant material contained therein. Also disclosed are a method and apparatus for preparing the sublingual dosage form, and compositions and kits comprising the sublingual dosage form.” — Patent US CA 2931486 A1
Formulation and Method for Increasing Oral Bioavailability of Drugs
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | November 2014Abstract: “The application discloses a formulation and method for increasing bioavailability of an orally administered drug.” — Patent US20140348926 A1
Anti-Tumoural Effects of Cannabinoid Combinations
GW Pharma | January 2014Abstract: “The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).” — US Patent 8632825 B2
United States Patent Application Publication for Phytocannabinoids in the Treatment of Cancer
Otsuka Pharmaceutical Co. Ltd. & GW Pharma Limited| March 2013Abstract: “This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.” — Patent US20130059018 A1
Use of Cannabidiol in the Treatment of Hepatitis
University Of South Carolina | November 2012Abstract: “Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind CB1 are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as Δ9-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.” — Patent US 20120302646 A1
Method for Predicting Autism Spectrum Disorders by Cannabinoid and Cannabinoid Receptor Expression
Stephen T. Schultz, Mauris N. DeSilva, Georgianna G. Gould | September 2012Abstract: “The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression.” — US Patent US20120225015 A1
Novel Treatment for Cough
Piomelli; Daniele | January 2006Abstract: “The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically administered cannabinoid inactivation inhibitors can also be used to ameliorate cough. The present invention also defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction.” — Patent 20060013777-A1
Methods of Purifying Cannabinoids from Plant Material
GW Pharmaceuticals | December 2005Abstract: “The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.” — Patent US20050266108 A1
Conversion of CBD to Delta8-THC and Delta9-THC
G. R. Barrie Webster, Manitoba (CA); Leonard P. Sarna, Manitoba (CA); Raphael Mechoulam | July 2004Abstract: “Methods of converting cannabidiol to Delta8-tetrahydrocannabinol or Delta9-tetrahydrocannabinol are described. The described methods produce higher yields and higher purity compared to prior art methods.” — Patent US20050266108 A1
United States Patent on Cannabinoids as Antioxidants and Neuroprotectants
The United States ofAmerica as represented by the Department of Health and Human Services | October 2003Abstract: “Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Non Psychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.” — Patent US6630507 B1
Use of Cannabinoids as Anti-Inflammatory Agents
The Mathilda and TerenceKennedy Institute of Rheumatology & Yissum Research and Development Company of the Hebrew University of Jerusalem | June 2002Abstract: “The application relates to the identification that cannabinoids, such as cannabidiol can be used to treat inflammatory diseases. Cannabinoids for use in treating inflammatory diseases, methods of treating inflammatory diseases and cannabinoids in combination with pharmaceutically acceptable carriers are claimed.” — Patent 6410588 B1
Cannabis Research Library
Over 1000 studies covering over 130 topics compiled for easy browsing.
